WO2010054281A1 - Implantable and refillable drug delivery reservoir - Google Patents
Implantable and refillable drug delivery reservoir Download PDFInfo
- Publication number
- WO2010054281A1 WO2010054281A1 PCT/US2009/063677 US2009063677W WO2010054281A1 WO 2010054281 A1 WO2010054281 A1 WO 2010054281A1 US 2009063677 W US2009063677 W US 2009063677W WO 2010054281 A1 WO2010054281 A1 WO 2010054281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic drug
- drug
- reservoir
- delivery
- catheter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0541—Cochlear electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M2039/0205—Access sites for injecting media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0276—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for introducing or removing fluids into or out of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0282—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body with implanted tubes connected to the port
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/054—General characteristics of the apparatus combined with other kinds of therapy with electrotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0662—Ears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/0565—Electrode heads
- A61N1/0568—Electrode heads with drug delivery
Definitions
- the present invention relates to medical implants, and more specifically to implantable drug delivery systems.
- U.S. Patent 7,044,942 (incorporated herein by reference) describes an implantable system for delivering therapeutic drugs which includes an implantable stimulation electrode which can deliver one or more therapeutic drugs to the surrounding tissue. There also is a separate implantable reservoir for containing the therapeutic drugs and supplying them to the electrode. The patent discusses that the reservoir may be refillable.
- a subcutaneous primary reservoir holds a primary volume of a therapeutic drug and is in fluid communication with an input port septum for receiving the therapeutic drug.
- a subcutaneous secondary reservoir is in fluid communication with the primary reservoir and holds a secondary volume of the therapeutic drug.
- the secondary reservoir includes a drug permeable surface for diffusion of the therapeutic drug into nearby tissue, and a priming septum for fluid exchange within the secondary reservoir.
- Embodiments may also include a diffusion channel providing the fluid communication between the primary reservoir and the secondary reservoir.
- a channel coil surrounding the diffusion channel for inducing ionic displacement of fluid within the diffusion channel from one reservoir to the other.
- the secondary reservoir may form a delivery catheter enclosing the secondary volume.
- the delivery catheter may contain a semi-permeable filter for mechanically filtering fluid flow through the catheter, for example, using a filter rod based on a drug eluting polymer or gel.
- the delivery catheter may include a silicone matrix superstructure.
- the apparatus may also include an input channel providing fluid communication between the input port septum and the primary reservoir.
- At least one of the reservoirs may include at least one internal control surface promoting controlled flow of fluid within the at least one of the reservoirs.
- one or more internal control surface surfaces may be arranged in a control labyrinth.
- a capillary tube arrangement may be used for controlling flow.
- Embodiments may include a pressure control element between the primary reservoir and the secondary reservoir preventing pressure transients between the primary reservoir and the secondary reservoir.
- the pressure control element may include a check valve arrangement or a capillary tube arrangement.
- Embodiments of the present invention also include an implantable drug delivery having an input port septum for receiving a therapeutic drug.
- An implantable delivery catheter holds a volume of the therapeutic drug and has a proximal end in fluid communication with the input port septum, a distal end including an output septum for removing fluid from the catheter, and a drug permeable surface for diffusion of the therapeutic drug into nearby tissue.
- Specific embodiments may also include an input channel providing fluid communication between the input port septum and the delivery catheter.
- the delivery catheter may be connected to an implantable stimulator housing containing signal processing circuitry.
- the implantable stimulator housing may be part of a cochlear implant system and the delivery catheter may be an element of an implantable stimulation electrode.
- the drug permeable surface may include a drug permeable membrane. Or there may be an arrangement of drug permeable slits and/or holes.
- the therapeutic drug fluid may be mixed with an osmotic agent such as a saline solution for accelerating diffusion of the therapeutic drug out of the secondary reservoir.
- a charge driver arrangement may be used to apply electric signals such as charge balanced asymmetric pulses for displacing the therapeutic drug within the apparatus by driving electrically charged molecular substances within the therapeutic drug.
- a pair of charge driver electrodes such as an active electrode in the primary reservoir and a ground electrode in the secondary reservoir displaces the therapeutic drug from the primary reservoir to the secondary reservoir over time to replenish the secondary reservoir.
- a magnetic driver arrangement such as a pair of magnets to apply magnetic forces for displacing the therapeutic drug within the apparatus by driving magnetic molecular substances within the therapeutic drug.
- the magnetic driver arrangement may include a repeller magnet in the primary reservoir and an attractor magnet in the secondary reservoir that displace the therapeutic drug from the primary reservoir to the secondary reservoir over time to replenish the secondary reservoir.
- the drive arrangement may include a magnet within one of the reservoirs and a magnet outside the secondary reservoir which may exert a magnetic attractive force on magnetic molecular substances within the therapeutic drug pulling them through the drug permeable surface into the nearby tissue.
- the delivery catheter may contain a semi -permeable filter for mechanically filtering fluid flow through the catheter.
- the semi-permeable filter may be a structural rod based on a drug eluting polymer or gel.
- the catheter may also include a silicone matrix superstructure.
- the drug permeable surface may include a drug permeable membrane and/or drug permeable slits or holes.
- Embodiments of the present invention include an apparatus for transferring fluid containing a therapeutic drug.
- a delivery syringe has a delivery piston for injecting a delivery volume of therapeutic drug fluid into an implanted system.
- a receiver syringe has a receiver piston for removing a withdrawal volume of fluid from the implanted system.
- a piston coupling rod rotates about a center coupling axis and is connected to each of the pistons so that when the delivery piston is pushed into the delivery syringe, the coupling rod rotates to push out the receiver piston the same amount.
- a syringe housing may contain both the delivery syringe and the receiver syringe.
- Embodiments are also directed to a method of delivering a therapeutic drug to an implanted system.
- a needle of a delivery syringe containing the therapeutic drug is inserted into an input port septum of an implantable primary reservoir.
- Another needle of a receiver syringe is inserted into a priming septum of an implantable secondary reservoir in fluid communication with the primary reservoir.
- the therapeutic drug is injected from the delivery syringe into the primary reservoir, and fluid is withdrawn from the secondary reservoir into the receiver syringe so as to prime the reservoirs with the therapeutic drug.
- the needles may be removed from the septums after the reservoirs have been primed, and the reservoirs can be subcutaneously implanted in a selected position in a patient after the needles have been removed. For example, they may be implanted adjacent to the skull of the patient.
- Embodiments of another method of introducing a therapeutic drug in an implanted drug reservoir arrangement start by inserting a needle of a delivery syringe containing the therapeutic drug through the skin of a patient into an input port septum of an implanted drug reservoir. Another needle of a receiver syringe is inserted through the skin of the patient into an output septum of the implanted drug reservoir. The therapeutic drug is injected from the delivery syringe into the drug reservoir, and fluid is withdrawn from the drug reservoir into the receiver syringe so as to introduce the therapeutic drug into the drug reservoir. The needles may be removed from the septums after the therapeutic drug has been introduced into the drug reservoir.
- Figure 1 shows an embodiment of an implantable drug delivery system.
- Figure 2 shows another embodiment of an implantable drug delivery system using a charge drive arrangement.
- Figure 3 shows principles of a magnetic drive arrangement as used by another embodiment of the present invention.
- Figure 4 shows an embodiment having a volume of therapeutic drug fluid in a delivery catheter.
- Figure 5 shows an embodiment having a semi-permeable filter in the form of a drug delivery rod.
- Figure 6 shows an embodiment in which an implantable delivery catheter is connected to the body of an implant housing.
- Figure 7 shows another embodiment having a primary reservoir and a secondary reservoir connected by a diffusion channel.
- Figure 8 shows an embodiment having one or more internal control surfaces to form a control labyrinth that promotes controlled flow of fluid.
- Figure 9 shows an embodiment having a pressure control element between the primary reservoir and the secondary reservoir for preventing pressure transients.
- Figure 10 shows a device having a delivery syringe and a receiver syringe in accordance with an embodiment of the present invention.
- Embodiments include a fillable and refillable implantable drug delivery system which does not increase its internal pressure while refilling. And electrical and/or magnetic pulses can be used to displace molecules within the therapeutic drug within the apparatus. Such embodiments and techniques are useful for delivering a solution of a therapeutic drug into target tissue such as a body cavity like the cochlea.
- Embodiments also include one or more subcutaneous drug delivery reservoirs that are transcutaneously refillable without increasing pressure.
- Embodiments also maintain homogeneity of a therapeutic drug within a drug delivery reservoir as the drug diffuses to the outside of the reservoir.
- Figure 1 shows an embodiment of an implantable drug delivery system 100 that includes a subcutaneous primary reservoir 101 that holds a primary volume of a therapeutic drug.
- the primary reservoir 101 includes an input port septum 104 for receiving the therapeutic drug and a corresponding an output port septum 105 for removing fluid.
- a diffusion channel 103 provides a fluid communication path from the primary reservoir 101 to a secondary reservoir 102 that holds a secondary volume of the therapeutic drug.
- the secondary reservoir 102 includes a drug permeable surface 107 such as a drug permeable membrane, slits or holes for diffusion of the therapeutic drug into nearby tissue, and a priming septum 106 for fluid exchange within the secondary reservoir 102.
- Fig. 1 also includes a channel coil 108 that surrounds the diffusion channel 103 for inducing ionic displacement of fluid within the diffusion channel from one reservoir to the other.
- the system may be filled with therapeutic drug fluid before implantation by inserting a needle of a delivery syringe containing the therapeutic drug fluid into the input port septum 104.
- a needle of a receiver syringe is inserted into the priming septum 106 and the therapeutic drug fluid is injected from the delivery syringe into the primary reservoir 101 while the receiver syringe withdraws fluid from the secondary reservoir 102, thereby priming the reservoirs with the therapeutic drug fluid.
- the needles are removed from the septums and the drug delivery system is ready to be subcutaneous Iy implanted in a selected position in a patient, for example, adjacent to the skull of the patient for use with a cochlear implant system.
- the implantable drug delivery system 100 allows refilling of the reservoirs 101 and 102, either with the same therapeutic drug or with a new therapeutic drug with a different molecular content.
- the refilling process does not raise pressure either within the internal volume of the drug delivery system 100 or in the surrounding tissue and fluid region outside the secondary reservoir 102.
- No special bacterial filter is needed because molecular diffusion preferentially occurs through the ion permeable membrane drug delivery surface 107, or through punctures in the drug delivery surface 107 that are smaller than bacteria size.
- FIG. 2 shows another similar embodiment of an implantable drug delivery system 200 which has just a single primary septum 201 on top of the primary reservoir 101. And instead of a channel coil arrangement, this embodiment uses a charge driver arrangement to for displacing the therapeutic drug within the apparatus by driving electrically charged molecular substances within the therapeutic drug.
- a pulse generator 204 e.g., from an implantable stimulator
- a ground electrode 203 in the secondary reservoir 102 completes the current path.
- a drive signal based on charge balanced asymmetric pulses such as the example shown in the bottom of Fig. 2 then can drive electrically charged molecular substances within the therapeutic drug, for example, to displace the therapeutic drug from the primary reservoir 101 to the secondary reservoir 102 over time to replenish the secondary reservoir.
- ground electrode 203 instead of placing the ground electrode 203 inside the secondary reservoir 102, in some embodiments it may be external to the secondary reservoir 102.
- Such an arrangement allows a drive signal based on charge balanced asymmetric pulses to displace the therapeutic drug from the primary reservoir 101, through the secondary reservoir 102, and by active diffusion through the drug permeable surface 107 into the nearby tissue, e.g., into the surrounding cochlear fluid or extra-cellular fluid.
- Such a charge driver arrangement may be especially effective if there are small ionic channels between the polymer matrix of the drug permeable surface 107 and the surrounding tissue.
- the pulse generator 204 advantageously may be located within the housing of a cochlear implant stimulator, which typically are designed to deliver charge balanced symmetric or asymmetric pulses.
- the drive signal may be based on use of tri-phasic pulses to provoke a net charge displacement in one direction of the electrodes.
- the associated insulated wiring for such embodiments both to and from the pulse generator 204 and between the electrodes 202 and 203 may run within the interior volume of the reservoirs, or within or along the walls and surfaces of the apparatus structures.
- some embodiments may use a magnetic drive arrangement based on the principles shown in Figure 3 for displacing the therapeutic drug within the apparatus by driving magnetic molecular substances within the therapeutic drug.
- a magnetic driver arrangement uses a repeller magnet 301 and an attractor magnet 302 that set up a magnetic field between them that displaces the therapeutic drug within the apparatus by driving magnetic molecular substances 303 within the therapeutic drug.
- a repeller magnet 301 and an attractor magnet 302 that set up a magnetic field between them that displaces the therapeutic drug within the apparatus by driving magnetic molecular substances 303 within the therapeutic drug.
- the attractor magnet 302 may be located within the secondary reservoir to displace the therapeutic drug fluid from the primary reservoir to the secondary reservoir over time to replenish the secondary reservoir.
- the magnets 301 and/or 302 may usefully be covered by a protective encapsulation layer.
- Figure 4 shows another embodiment of an implantable drug delivery apparatus in which the arrangement of the primary reservoir 101 and its input septum 104 and output septum 105 are as in Fig. 1, but the secondary reservoir 401 is elongated to form a delivery catheter that encloses the secondary volume.
- the proximal end of delivery catheter secondary reservoir 401 is in fluid communication with the input septum 104 while the distal end includes an output septum 403 for removing fluid from the secondary reservoir 401 when filling or refilling the system.
- a drug permeable surface 402 such as an ion permeable diffusion membrane diffuses the therapeutic drug fluid into the surrounding tissues and fluids.
- the interior of the secondary reservoir 401 may include a semi-permeable filter such as the drug delivery rod 502 shown in Figure 5 for mechanically filtering fluid flow through the catheter.
- the drug delivery rod 502 may be in the specific form of a drug eluting gel or drug eluting polymer such as a drug eluting silicone rod.
- a drug delivery rod 502 is then embedded or incorporated into the main superstructure of the secondary reservoir 401, which may be, for example, a silicone matrix 501.
- the silicone matrix 501 may include a slit opening 503 that allows hydration of the drug eluting material by the surrounding fluid.
- the elongated form of the secondary reservoir 401 may be pre-shaped to have a bend in it to accommodate placement around internal body structures. Or the secondary reservoir 401 may be flexible to be bendable around such internal body structures.
- FIG. 6 shows another embodiment in which an implantable delivery catheter 401 is connected to the body of an implant housing 603, such as a cochlear implant stimulator housing.
- the delivery catheter 401 may be an internal volume within a stimulator electrode array which is implanted, for example, in the cochlea of a hearing impaired patient.
- the electrode array in such an embodiment includes a drug permeable surface as described above (e.g., an ion or molecule permeable membrane and/or an arrangement of multiple diffusion slits or holes) through which the therapeutic drug diffuses into the surrounding tissue or fluid.
- the therapeutic drug is delivered to the delivery catheter 401 via an arrangement of an input septum 601 over an input port 602, through an input channel 604 and the implant housing 603.
- priming septum 106 may be used before implantation to withdraw existing fluid within the delivery catheter 401 to initially fill the system. After implantation, additional therapeutic drug fluid can be periodically added transcutaneous Iy through the input septum 601, which located is just under the skin of the patient.
- Figure 7 shows another embodiment having a primary reservoir 701 and a secondary reservoir 702 connected by a diffusion channel 703.
- the secondary reservoir 702 includes a priming septum 710 and a drug delivery surface 711 as described above with regards to other embodiments.
- an input channel 708 provides fluid communication between the primary reservoir 701 and an input port 706 having an input septum 704.
- an output channel 709 also provides fluid communication between the primary reservoir 701 and an output port 707 having an output septum 705.
- Initial filling of the system may occur before implantation using the input septum 704 and priming septum 710.
- the system can be filled/replenished using a delivery syringe containing the therapeutic drug fluid to refill the primary reservoir 701 transcutaneous Iy through the skin of a patient into the input septum 704, while a receiver syringe under negative pressure (i.e., withdrawing the plunger) permits air or old fluid to be withdrawn transcutaneously through the output septum 705 and the skin into the receiver syringe, thereby refilling/replenishing the primary reservoir 701.
- both the delivery syringe needle and the receiver needle are removed.
- Embodiments may also include an internal flow control arrangement for correctly and reliably directing fluid flow within the primary reservoir, for example to maintain a desired concentration of therapeutic drug within the fluid in the reservoir.
- Figure 8 shows a primary reservoir 800 having one or more internal control surfaces 801 to form a control labyrinth that promotes controlled flow of fluid within the primary reservoir 800.
- Fig. 8 A shows use of a single control surface 801, in other embodiments, there may be multiple such control surfaces arranged to form a more complicated control labyrinth.
- a capillary tube arrangement such as the one shown at the bottom of Fig. 9 may be used as a control labyrinth within the primary reservoir 800.
- Embodiments may also include a pressure control element between the primary reservoir and the secondary reservoir for preventing pressure transients between the primary reservoir and the secondary reservoir.
- Limiting pressure transients between the primary reservoir and the secondary reservoir during fluid filling operations also serves to prevent pressure transients in the surrounding tissue and fluid region outside the secondary reservoir.
- a pressure control element may be in the specific form of a check valve arrangement at the opening to the diffusion channel such as single flap check valve 901 or double flap check valve 902. If pressure increases in the primary reservoir during fluid filling, the check valve 901 or 902 closes to prevent a pressure transient in the secondary reservoir.
- a capillary tube arrangement 903 at the beginning of the diffusion channel may serve the same purpose by allowing diffusion but providing significant resistance to any pressure driven fluid flow.
- FIG. 10 shows one example of such a fluid replacement device 1000 which contains in a single housing both a delivery syringe 1001 having a delivery piston 1003 and a receiver syringe 1002 having a receiver piston 1004.
- a piston coupling rod 1005 which rotates about a coupling axis 1006 so that when the delivery piston is pushed into the delivery syringe 1001, the coupling rod 1005 rotates to push out the receiver piston 1004 the same amount.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011535713A JP5372166B2 (en) | 2008-11-10 | 2009-11-09 | Implantable refillable drug delivery container |
CN2009801448898A CN102209574A (en) | 2008-11-10 | 2009-11-09 | Implantable and refillable drug delivery reservoir |
EP09752640.4A EP2379165B1 (en) | 2008-11-10 | 2009-11-09 | Implantable and refillable drug delivery reservoir |
AU2009313286A AU2009313286B2 (en) | 2008-11-10 | 2009-11-09 | Implantable and refillable drug delivery reservoir |
CA2743252A CA2743252A1 (en) | 2008-11-10 | 2009-11-09 | Implantable and refillable drug delivery reservoir |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11281808P | 2008-11-10 | 2008-11-10 | |
US61/112,818 | 2008-11-10 | ||
US24320909P | 2009-09-17 | 2009-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010054281A1 true WO2010054281A1 (en) | 2010-05-14 |
Family
ID=41395483
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/063721 WO2010054308A1 (en) | 2008-11-10 | 2009-11-09 | Hydrogel-filled drug delivery reservoirs |
PCT/US2009/063677 WO2010054281A1 (en) | 2008-11-10 | 2009-11-09 | Implantable and refillable drug delivery reservoir |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/063721 WO2010054308A1 (en) | 2008-11-10 | 2009-11-09 | Hydrogel-filled drug delivery reservoirs |
Country Status (6)
Country | Link |
---|---|
US (2) | US8750988B2 (en) |
EP (1) | EP2376180B1 (en) |
CN (1) | CN102271754B (en) |
AU (1) | AU2009313316B2 (en) |
CA (1) | CA2745453C (en) |
WO (2) | WO2010054308A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8190271B2 (en) | 2007-08-29 | 2012-05-29 | Advanced Bionics, Llc | Minimizing trauma during and after insertion of a cochlear lead |
US8271101B2 (en) | 2007-08-29 | 2012-09-18 | Advanced Bionics | Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130225905A1 (en) * | 2010-08-19 | 2013-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Device that is implantable in the temporal bone for delivering a material, and hearing aid provided with such a device |
AU2013288825B2 (en) | 2012-07-13 | 2016-04-14 | Med-El Elektromedizinische Geraete Gmbh | Implantable fluid delivery system with floating mass transducer driven pump |
FR3006594A1 (en) * | 2013-06-11 | 2014-12-12 | Sorin Crm Sas | IMPLANTABLE MICROSONDE FOR DETECTION / STIMULATION INCORPORATING AN ANTI-INFLAMMATORY AGENT |
EP3041444B1 (en) * | 2013-09-06 | 2023-07-19 | Med-El Elektromedizinische Geraete GmbH | Electrode contact with hydrogel covering |
CN104644545A (en) * | 2015-02-27 | 2015-05-27 | 苏州丝美特生物技术有限公司 | Controlled-release and slow-release silk fibroin gel preparation for treating inner ear disease |
WO2015196055A1 (en) * | 2014-06-19 | 2015-12-23 | California Institute Of Technology | Small molecule transport device for drug delivery or waste removal |
CN106659886B (en) * | 2014-08-27 | 2019-11-08 | 神经毫微股份公司 | Transplant method of the medical equipment into nerve fiber |
US11045644B2 (en) | 2015-08-13 | 2021-06-29 | University Of Southern California | Cuff electrode with lysing agent |
US11724080B2 (en) * | 2016-02-26 | 2023-08-15 | Neuronano Ab | Method of implantation of cell aggregates and tissue fragments |
EP3419714A4 (en) * | 2016-02-26 | 2019-09-25 | Neuronano AB | Method of providing an implantation site in soft tissue |
KR101961415B1 (en) * | 2016-04-27 | 2019-07-17 | 서강대학교산학협력단 | Tubeless implantable drug infusion system |
CN106924818B (en) * | 2017-02-16 | 2020-05-12 | 南方医科大学珠江医院 | Drug-loaded gel and preparation method and application thereof |
US11273295B2 (en) | 2018-04-19 | 2022-03-15 | Spiral Therapeutics, Inc. | Inner ear drug delivery devices and methods of use |
US20210308371A1 (en) * | 2018-08-24 | 2021-10-07 | Cochlear Limited | Mass transport inside mammals |
US20210402161A1 (en) * | 2018-11-02 | 2021-12-30 | Bionaut Labs Ltd. | Magnetomechanic triggering ofpayload release from miniaturized devices |
WO2020141997A1 (en) * | 2019-01-04 | 2020-07-09 | Neuronano Ab | Probe for implantation into nervous tissue comprising a microelectrode or a set of microelectrodes |
US11890438B1 (en) * | 2019-09-12 | 2024-02-06 | Cochlear Limited | Therapeutic substance delivery |
US20230092955A1 (en) * | 2021-09-22 | 2023-03-23 | Celanese Eva Performance Polymers Llc | Refillable Implantable Device for Delivering a Drug Compound |
WO2024038420A1 (en) * | 2022-08-19 | 2024-02-22 | Cochlear Limited | Substance delivery inside mammals |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002102278A2 (en) * | 2001-06-18 | 2002-12-27 | Durect Corporation | Device and method for delivering microdoses of agent to the ear |
US20030097121A1 (en) * | 2001-10-24 | 2003-05-22 | Claude Jolly | Implantable fluid delivery apparatuses and implantable electrode |
US20070255237A1 (en) * | 2006-05-01 | 2007-11-01 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4207554A (en) * | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
US4573994A (en) | 1979-04-27 | 1986-03-04 | The Johns Hopkins University | Refillable medication infusion apparatus |
US4400590A (en) * | 1980-12-22 | 1983-08-23 | The Regents Of The University Of California | Apparatus for multichannel cochlear implant hearing aid system |
US4419995A (en) * | 1981-09-18 | 1983-12-13 | Hochmair Ingeborg | Single channel auditory stimulation system |
US4588394A (en) * | 1984-03-16 | 1986-05-13 | Pudenz-Schulte Medical Research Corp. | Infusion reservoir and pump system |
DE3821970C1 (en) | 1988-06-29 | 1989-12-14 | Ernst-Ludwig Von Dr. 8137 Berg De Wallenberg-Pachaly | |
US5458631A (en) | 1989-01-06 | 1995-10-17 | Xavier; Ravi | Implantable catheter with electrical pulse nerve stimulators and drug delivery system |
US5119832A (en) | 1989-07-11 | 1992-06-09 | Ravi Xavier | Epidural catheter with nerve stimulators |
US5674192A (en) * | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5087243A (en) | 1990-06-18 | 1992-02-11 | Boaz Avitall | Myocardial iontophoresis |
US5421818A (en) | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
US5928229A (en) | 1993-11-08 | 1999-07-27 | Rita Medical Systems, Inc. | Tumor ablation apparatus |
US5843093A (en) * | 1994-02-09 | 1998-12-01 | University Of Iowa Research Foundation | Stereotactic electrode assembly |
US6129685A (en) | 1994-02-09 | 2000-10-10 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
US5697975A (en) * | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
US5607407A (en) | 1994-05-09 | 1997-03-04 | Tolkoff; Marc J. | Catheter assembly |
US5509888A (en) * | 1994-07-26 | 1996-04-23 | Conceptek Corporation | Controller valve device and method |
US5854987A (en) * | 1995-02-22 | 1998-12-29 | Honda Giken Kogyo Kabushiki Kaisha | Vehicle steering control system using navigation system |
AU722787B2 (en) | 1996-02-26 | 2000-08-10 | Med-El Elektromedizinische Gerate Gmbh | Structure, method of use, and method of manufacture of an implanted hearing prosthesis |
AU722310B2 (en) | 1996-03-13 | 2000-07-27 | Med-El Elektromedizinische Gerate Gmbh | Device and method for implants in ossified cochleas |
US5697951A (en) * | 1996-04-25 | 1997-12-16 | Medtronic, Inc. | Implantable stimulation and drug infusion techniques |
EP0902999A1 (en) | 1996-06-04 | 1999-03-24 | Murphy, Timothy M. | A device for transferring electromagnetic energy between primary and secondary coils |
ES2214627T3 (en) | 1996-06-20 | 2004-09-16 | Advanced Bionics Corporation | SELF-ADJUSTABLE COCLEAR IMPLANT SYSTEM. |
US6156728A (en) | 1996-11-01 | 2000-12-05 | Genentech, Inc. | Treatment of inner ear hair cells |
AU746636B2 (en) * | 1997-03-10 | 2002-05-02 | Med-El Elektromedizinische Gerate Gmbh | Apparatus and method for perimodiolar cochlear implant with retro-positioning |
AU750976B2 (en) | 1997-05-01 | 2002-08-01 | Med-El Elektromedizinische Gerate Ges.M.B.H. | Apparatus and method for a low power digital filter bank |
US6119044A (en) | 1997-06-02 | 2000-09-12 | Advanced Bionics Corporation | Cochlear electrode array with positioning stylet |
US5997524A (en) | 1997-07-18 | 1999-12-07 | Vasca, Inc. | Catheter assembly for percutaneous access to subcutaneous port |
US6190352B1 (en) * | 1997-10-01 | 2001-02-20 | Boston Scientific Corporation | Guidewire compatible port and method for inserting same |
USD419677S (en) * | 1997-11-04 | 2000-01-25 | Med-El Elektromedizinische Gerate Ges.M.B.H. | Speech processor for use with a cochlear implant |
US6093144A (en) * | 1997-12-16 | 2000-07-25 | Symphonix Devices, Inc. | Implantable microphone having improved sensitivity and frequency response |
US6231604B1 (en) | 1998-02-26 | 2001-05-15 | Med-El Elektromedizinische Gerate Ges.M.B.H | Apparatus and method for combined acoustic mechanical and electrical auditory stimulation |
US6348070B1 (en) * | 1998-04-17 | 2002-02-19 | Med-El Elektromedizinische Gerate Ges.M.B.H | Magnetic-interference-free surgical prostheses |
US6361494B1 (en) | 1998-05-18 | 2002-03-26 | Med-El. Elektromedizinische Gerate Ges.M.B.H. | Electrode and method for measuring muscle activity in the pharyngeal airways |
US6266568B1 (en) | 1998-06-02 | 2001-07-24 | Advanced Bionics Corporation | Inflatable cochlear electrode array and method of making same |
DE19829637C2 (en) * | 1998-07-02 | 2000-10-19 | Implex Hear Tech Ag | Medical implant |
US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
US6309410B1 (en) | 1998-08-26 | 2001-10-30 | Advanced Bionics Corporation | Cochlear electrode with drug delivery channel and method of making same |
US6968238B1 (en) | 1998-08-26 | 2005-11-22 | Kuzma Janusz A | Method for inserting cochlear electrode and insertion tool for use therewith |
US6862805B1 (en) * | 1998-08-26 | 2005-03-08 | Advanced Bionics Corporation | Method of making a cochlear electrode array having current-focusing and tissue-treating features |
US6397110B1 (en) | 1998-08-26 | 2002-05-28 | Advanced Bionics Corporation | Cochlear electrode system including detachable flexible positioner |
US6195586B1 (en) | 1998-08-26 | 2001-02-27 | Advanced Bionics Corporation | Space-filling cochlear electrode |
DE19853299C2 (en) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Catheter for the application of medication in fluid spaces of the human inner ear |
US6535153B1 (en) * | 1999-02-04 | 2003-03-18 | Med-El Electromedizinische Gerate Ges.M.B.H. | Adaptive sigma-delta modulation with one-bit quantization |
US6309401B1 (en) * | 1999-04-30 | 2001-10-30 | Vladimir Redko | Apparatus and method for percutaneous implant of a paddle style lead |
US6259951B1 (en) | 1999-05-14 | 2001-07-10 | Advanced Bionics Corporation | Implantable cochlear stimulator system incorporating combination electrode/transducer |
AU769596B2 (en) * | 1999-07-21 | 2004-01-29 | Med-El Elektromedizinische Gerate Gmbh | A circuit and method for generating sign-correlated simultaneous pulsatile |
US6471689B1 (en) * | 1999-08-16 | 2002-10-29 | Thomas Jefferson University | Implantable drug delivery catheter system with capillary interface |
ATE376443T1 (en) * | 1999-08-26 | 2007-11-15 | Med El Elektromed Geraete Gmbh | TRANSCUTANE ELECTRICAL NERVE STIMULATION BASED ON CHANNEL-SPECIFIC SAMPLING SEQUENCES |
US6358281B1 (en) | 1999-11-29 | 2002-03-19 | Epic Biosonics Inc. | Totally implantable cochlear prosthesis |
US6556870B2 (en) | 2000-01-31 | 2003-04-29 | Med-El Elektromedizinische Geraete Gmbh | Partially inserted cochlear implant |
DE10018360C2 (en) * | 2000-04-13 | 2002-10-10 | Cochlear Ltd | At least partially implantable system for the rehabilitation of a hearing impairment |
DE10018334C1 (en) * | 2000-04-13 | 2002-02-28 | Implex Hear Tech Ag | At least partially implantable system for the rehabilitation of a hearing impairment |
US6628991B2 (en) | 2000-04-28 | 2003-09-30 | Advanced Bionics Corporation | Minimally-invasive access into the cochlea for electrode insertion and fluid delivery |
US20020147424A1 (en) * | 2000-12-26 | 2002-10-10 | Alvin Ostrow | Transdermal magnetic drug delivery system and method |
US7050858B1 (en) * | 2001-04-06 | 2006-05-23 | Advanced Bionics Corporation | Insertion tool for placement of electrode system inside the cochlear lumen |
US20070088335A1 (en) * | 2001-10-24 | 2007-04-19 | Med-El Elektromedizinische Geraete Gmbh | Implantable neuro-stimulation electrode with fluid reservoir |
WO2003084074A1 (en) | 2002-03-28 | 2003-10-09 | Med-El Elektromedizinische Geräte G.M.B.H. | A system and method for adaptive sigma-delta modulation |
AU2003233025B2 (en) * | 2002-04-01 | 2008-04-10 | Med-El Elektromedizinische Geraete Gmbh | Reducing effect of magnetic and electromagnetic fields on an implants magnet and/or electronic |
WO2004024212A2 (en) | 2002-09-10 | 2004-03-25 | Vibrant Med-El Hearing Technology Gmbh | Implantable medical devices with multiple transducers |
US7315763B2 (en) | 2002-09-19 | 2008-01-01 | Advanced Bionics Corporation | Cochlear implant electrode and method of making same |
US7319906B2 (en) | 2002-09-19 | 2008-01-15 | Advanced Bionics Corporation | Cochlear implant electrode and method of making same |
US20040059228A1 (en) * | 2002-09-23 | 2004-03-25 | Scimed Life Systems, Inc. | Systems and methods for flushing catheters |
US8021359B2 (en) * | 2003-02-13 | 2011-09-20 | Coaptus Medical Corporation | Transseptal closure of a patent foramen ovale and other cardiac defects |
US8691258B2 (en) * | 2003-12-12 | 2014-04-08 | Medtronic, Inc. | Anti-infective medical device |
WO2006079055A2 (en) * | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
US7884136B2 (en) * | 2005-06-27 | 2011-02-08 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
US7555352B2 (en) * | 2005-11-08 | 2009-06-30 | Cochlear Limited | Implantable carrier member having a non-communicative lumen |
US8444609B2 (en) | 2006-04-28 | 2013-05-21 | Medtronic, Inc. | Implantable therapeutic substance delivery system with catheter access port block and method of use |
EP2047884B1 (en) * | 2007-10-09 | 2018-04-04 | Cochlear Limited | Implantable component having an accessible lumen and a drug delivery capsule for introduction into same |
-
2009
- 2009-11-09 CA CA2745453A patent/CA2745453C/en active Active
- 2009-11-09 WO PCT/US2009/063721 patent/WO2010054308A1/en active Application Filing
- 2009-11-09 CN CN200980154218.XA patent/CN102271754B/en active Active
- 2009-11-09 US US12/614,959 patent/US8750988B2/en active Active
- 2009-11-09 AU AU2009313316A patent/AU2009313316B2/en active Active
- 2009-11-09 US US12/614,552 patent/US20100121256A1/en not_active Abandoned
- 2009-11-09 EP EP09752644.6A patent/EP2376180B1/en active Active
- 2009-11-09 WO PCT/US2009/063677 patent/WO2010054281A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002102278A2 (en) * | 2001-06-18 | 2002-12-27 | Durect Corporation | Device and method for delivering microdoses of agent to the ear |
US20030097121A1 (en) * | 2001-10-24 | 2003-05-22 | Claude Jolly | Implantable fluid delivery apparatuses and implantable electrode |
US20070255237A1 (en) * | 2006-05-01 | 2007-11-01 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8190271B2 (en) | 2007-08-29 | 2012-05-29 | Advanced Bionics, Llc | Minimizing trauma during and after insertion of a cochlear lead |
US8271101B2 (en) | 2007-08-29 | 2012-09-18 | Advanced Bionics | Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead |
Also Published As
Publication number | Publication date |
---|---|
CA2745453C (en) | 2015-06-16 |
EP2376180A1 (en) | 2011-10-19 |
CN102271754A (en) | 2011-12-07 |
US8750988B2 (en) | 2014-06-10 |
EP2376180B1 (en) | 2017-06-28 |
US20100121256A1 (en) | 2010-05-13 |
AU2009313316A1 (en) | 2011-06-23 |
CA2745453A1 (en) | 2010-05-14 |
CN102271754B (en) | 2014-07-16 |
AU2009313316B2 (en) | 2013-07-18 |
US20100121422A1 (en) | 2010-05-13 |
WO2010054308A1 (en) | 2010-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100121256A1 (en) | Implantable and Refillable Drug Delivery Reservoir | |
EP2108399B1 (en) | Implantable neuro-stimulation electrode with fluid reservoir | |
EP1441679B1 (en) | Implantable fluid delivery apparatuses and implantable electrode | |
EP2379165B1 (en) | Implantable and refillable drug delivery reservoir | |
AU2009305745B2 (en) | Inner ear drug delivery device and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980144889.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09752640 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011535713 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2743252 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009313286 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009313286 Country of ref document: AU Date of ref document: 20091109 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2009752640 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009752640 Country of ref document: EP |